 |
Controversies in Late-Onset Hypogonadism: A Panel Discussion CME Author Information and Disclosures Release Date: April 29, 2008; Valid for credit through April 29, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Controversies in Late-Onset Hypogonadism: A Panel DiscussionAndre T. Guay, MD, FACP, FACE; Chad W.M. Ritenour, MD; Matt Rosenberg, MD, BAAvailable As: Slides/Video | Slides/Transcript
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review problematic issues in diagnosing male androgen deficiency -- the nonspecificity of symptoms, the lack of unanimously accepted norms for testosterone levels, issues in the measurement of testosterone levels, laboratory assay variability, and selection of
screening questionnaire
- Discuss issues of safety in the treatment of male androgen deficiency
- Review evidence for the association of androgen deficiency with chronic conditions such as metabolic syndrome and diabetes
Authors and Disclosures Matt T. Rosenberg, MD
Disclosure: Matt T. Rosenberg, MD,
has disclosed that he has served on the speaker's bureaus of Allergan, Astellas, Forest, GlaxoSmithKline, Novartis, Ortho-McNeil, Sanofi-Synthelabo, and Schering-Plough. Dr. Rosenberg has also disclosed that he has served as a consultant to Astellas, GlaxoSmithKline, Ortho-McNeil, Pfizer, Roche, Sanofi-Synthelabo, and Schering-Plough. Chad W.M. Ritenour, MD
Disclosure: Chad W.M. Ritenour, MD, has disclosed that he
has received grants for clinical research from AstraZeneca and Photocure. Dr. Ritenour has also disclosed that he has served as an advisor or consultant to Coloplast. Andre T. Guay, MD, FACP, FACE
Disclosure: Andre T. Guay, MD, FACP, FACE, has disclosed that he has received grants for clinical research from Auxilium, and that he has received grants for educational activities from Solvay, Auxilium, Indevus, Bayer, and
Schering AG. Dr. Guay has also disclosed that he has served as an advisor or consultant to Solvay, Auxilium, Indevus, Bayer, and Schering AG. David McNeel
Disclosure: David McNeel has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
